99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans.
In recent years, imaging tumors with receptor-specific biomolecules has been the focus of increasing interest. Vasoactive intestinal peptide (VIP) has a high affinity for specific receptors that are expressed in high density on a large number of malignant tumors. VIP was modified (TP 3654) without compromising its biologic activity and labeled with 99mTc. Pharmacokinetics and feasibility studies were performed in 3 healthy volunteers and 11 patients with a history of cancer. Imaging was performed for up to 2 h after injection. Within 24 h after injection of 99mTc-TP 3654 (370-555 MBq/5 microg), approximately 70% of the tracer cleared through the kidneys and 20% through the liver. Blood clearance was rapid. No adverse reaction was noted in any subject. All known tumors were clearly delineated within 20 min. Findings were compared with the results of 99mTc-methoxyisobutyl isonitrile, CT, MRI, or histology. There was concordance in 9 patients. In the other 2 patients, only the VIP scan was positive for tumors known to express VIP receptors. The early results of imaging tumors with 99mTc-VIP are promising and warrant further study.
Thakur
M L
ML
Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Marcus
C S
CS
Saeed
S
S
Pallela
V
V
Minami
C
C
Diggles
L
L
Le Pham
H
H
Ahdoot
R
R
Kalinowski
E A
EA
D000328:Adult; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007553:Isotope Labeling; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000000981:diagnostic imaging*; D009842:Oligopeptides / Q000493:pharmacokinetics; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013667:Technetium; D013997:Time Factors; D014660:Vasoactive Intestinal Peptide / Q000493:pharmacokinetics
D009842:Oligopeptides; D019275:Radiopharmaceuticals; C117473:TP 3654; D014660:Vasoactive Intestinal Peptide; D013667:Technetium